List of works - Simona Colla

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

scientific article published on 14 November 2006

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

scientific article published on 31 July 2015

Angiogenic switch in multiple myeloma.

scientific article

Angiopoietin-1 and myeloma-induced angiogenesis.

scientific article

Angiopoietins expression by human myeloma cells

scientific article published in June 2003

Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients

scientific article published on 20 May 2010

CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.

scientific article published in August 2008

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point

scientific article published on 22 October 2015

Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.

scientific article published on 12 May 2008

Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes

scientific article

Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.

scientific article published on 4 December 2009

Do human myeloma cells directly produce basic FGF?

scientific article

Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?

scientific article published on 15 January 2004

Down-regulation of EZH2 expression in myelodysplastic syndromes

scientific article published on 26 February 2016

Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis.

scientific article published on March 2004

Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion

scientific article published on 24 June 2015

Dysfunctional telomeres and hematological disorders.

scientific article published on 4 January 2018

Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells

scientific article published in June 1999

Erratum: Corrigendum: Passenger deletions generate therapeutic vulnerabilities in cancer

scientific article published in Nature

Erratum: Telomere dysfunction induces metabolic and mitochondrial compromise

scholarly article published in Nature

Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer

scientific article published on 3 March 2015

HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.

scientific article published on 23 November 2010

Hematologic Malignancies With Extramedullary Spread of Disease

scientific article published in May 2003

Hematopoiesis under telomere attrition at the single-cell resolution

scientific article published on 25 November 2021

Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients

scientific article published on 6 October 2005

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease

scientific article published on 8 August 2002

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.

scientific article published on 24 January 2013

ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma

scientific article published on 9 June 2017

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

scientific article published on 11 January 2017

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

scientific article published on 3 January 2018

Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients

scientific article published on 15 January 2006

KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice

scientific article published on 01 October 2018

Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cells

scientific article published in February 2005

Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells

scientific article

Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells

scientific article published on 02 September 2010

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

scientific article

Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.

scientific article

New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

scientific article published in August 2004

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

scientific article

PAF promotes stemness and radioresistance of glioma stem cells.

scientific article published on 9 October 2017

PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.

scientific article published in August 2016

PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network

scientific article published on 23 May 2011

Passenger deletions generate therapeutic vulnerabilities in cancer

scientific article

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

scientific article published on 02 December 2016

Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis

scientific article published on 13 March 2003

RNA processing: a new player of genomic instability in multiple myeloma.

scientific article published on July 2017

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

scientific article published on 03 March 2022

Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.

scientific article published on 8 February 2017

Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome

scientific article published on May 2015

Telomere dysfunction induces metabolic and mitochondrial compromise.

scientific article

The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment

scientific article published in September 2004

The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation

scientific article published on 31 May 2019

The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angio

scientific article published on 11 September 2007

The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.

scientific article published on 25 October 2010

Transforming growth factor beta3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis

scientific article published on 01 July 2000

Update on the pathogenesis of osteolysis in multiple myeloma patients

scientific article published in December 2004

e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?

scientific article

microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. ⬇️

scientific article

List of works by Simona Colla

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

Angiogenic switch in multiple myeloma.

Angiopoietin-1 and myeloma-induced angiogenesis.

Angiopoietins expression by human myeloma cells

Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients

CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point

Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.

Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes

Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.

Do human myeloma cells directly produce basic FGF?

Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?

Down-regulation of EZH2 expression in myelodysplastic syndromes

Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis.

Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion

Dysfunctional telomeres and hematological disorders.

Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells

Erratum: Corrigendum: Passenger deletions generate therapeutic vulnerabilities in cancer

Erratum: Telomere dysfunction induces metabolic and mitochondrial compromise

Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer

HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.

Hematologic Malignancies With Extramedullary Spread of Disease

Hematopoiesis under telomere attrition at the single-cell resolution

Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.

ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients

KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice

Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cells

Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells

Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.

New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

PAF promotes stemness and radioresistance of glioma stem cells.

PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.

PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network

Passenger deletions generate therapeutic vulnerabilities in cancer

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis

RNA processing: a new player of genomic instability in multiple myeloma.

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.

Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome

Telomere dysfunction induces metabolic and mitochondrial compromise.

The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment

The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation

The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angio

The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.

Transforming growth factor beta3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis

Update on the pathogenesis of osteolysis in multiple myeloma patients

e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?

microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. ⬇️

mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy